INTRODUCTION

Lowering homocysteine (HCY) is a sulfur-containing amino acid produced by demethylation of the essential amino acid methionine (Dennis, Nurko, & Robinson, 1997). Several studies have confirmed that elevated serum HCY level is a risk factor for cardiovascular and cerebrovascular diseases (Dikmen et al., 2006; Kwon, Lee, Bae, & Kang, 2014; Wald, Law, & Morris, 2002; Yokote, Shiraishi, Shintani, & Shiigai, 2007). A persistent elevated serum HCY level damages endothelial cells in the cerebral artery, gradually induces
atherosclerosis to stenosis and eventually leads to ischemic stroke (Clarke et al., 1991; McCully, 1969; Zhang et al., 2012).

Middle cerebral artery (MCA) stenosis leading to cerebral infarction characterized by impaired motor and/or language function is an important form of cerebral arteriosclerosis (Jeng et al., 2017). A previous study proposed that elevated serum HCY level is associated with MCA stenosis (Huang et al., 2007). However, several secondary prevention clinical trials have revealed that reductions in serum HCY level with B vitamins and folic acid supplementation did not have beneficial effects on vascular outcomes (Armitage et al., 2010; Bonaa et al., 2006; Lonn et al., 2006). Therefore, the association between serum HCY level and MCA stenosis may be complicated.

Given the lack of research on the association between serum HCY level and MCA stenosis, the purpose of this cross-sectional study was to further investigate the association and provide more evidence for prevention of ischemic stroke.

2 | METHODS

2.1 | Subjects

A total of 412 patients (35–93 years old) in the Neurology Department were included in this study from June 2017 to September 2017 in the Luoyang Central Hospital affiliated to Zhengzhou University. Inclusion criteria were as follows: integrated medical records and valid MCA imaging. Exclusion criteria were as follows: medical records deficiency, tumors, severe malnutrition and kidney failure. All subjects signed informed consent forms before the study. The study was approved by the ethics committee of the Luoyang Central Hospital.

2.2 | Clinical vascular risk factors

All data were collected from the integrated medical records of patients in the Neurology Department. Smoking status was recorded as never or not in males. Hypertension was diagnosed when blood pressure was ≥140/90 mmHg or with a self-reported history of hypertension or current antihypertensive treatment. Diabetes mellitus was confirmed in patients with fasting blood glucose levels >7.0 mmol/L or with a self-reported history of diabetes or antidiabetic drug or insulin use. Coronary heart disease was confirmed in patients with a self-reported history and antiplatelet drug use. Atrial fibrillation was diagnosed using electrocardiogram and stethoscope or a self-reported history or anticoagulant drug use. Ischemic stroke was confirmed in patients with a self-reported history and antiplatelet drug use.

2.3 | Biochemical vascular risk factors

Serum biochemical vascular risk factors, such as total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), fasting blood glucose, HbA1c, uric acid, and HCY were measured using standard laboratory techniques.

2.4 | Brain MRA

Brain MRA was performed in all subjects using a 3.0 T machine (Magnetom Verio, Siemens AG), with six slabs, each including 40 axial slices of 0.5-mm thickness and no interslice gaps. The 3D TOF images were acquired with the following parameters: TR/TE, 21/3.6 ms; flip angle, 15°; field of view, 219 × 219 mm; matrix number, 768 × 768; and axial slice thickness, 0.7 mm (Chen et al., 2015). MCA, including M1, M2, and M3, was classified into stenosis or no stenosis.

2.5 | Statistical analyses

The data are described as the mean ± standard deviations (SD) for quantitative data, frequencies, and percent for qualitative data. The differences in factors in two groups were assessed using chi-square tests or Student’s t-tests according to the data type. The association between MCA stenosis and the indicated variables was analyzed using bivariate logistic regression analysis. Data were analyzed using the Statistical Package for the Social Sciences (SPSS) 17.0 on Windows 7.0. p < 0.05 was considered statistically significant.

3 | RESULTS

3.1 | Difference in the indicated factors between the no MCA stenosis group and the MCA stenosis group at baseline

Four hundred and twelve patients (209 males and 203 females; mean age 66.29 years old) were classified into two groups: the no MCA stenosis group (n = 315) and the MCA stenosis group (n = 97). The demographic characteristics and clinical and biochemical vascular risk factors are shown in Table 1. Because this was a cross-sectional study, the age of patients in the MCA stenosis group was older than that in the no MCA stenosis group, and the ratio of females were higher in the MCA stenosis group. In accord with the age difference in the two groups, coronary heart disease (p = 0.030) and ischemic stroke (p = 0.040) were more prevalent in the MCA stenosis group. However, there was no significant difference (p = 0.325) in the HCY levels between the two groups.

3.2 | Association between MCA stenosis and the indicated factors at baseline

To analyze the association between MCA stenosis and the indicated factors, bivariate logistic regression analysis was performed. MCA stenosis was defined as 1, and no MCA stenosis was defined as 0. Males were defined as 1, and females were defined as 0. Smoking, hypertension, diabetes mellitus, coronary heart disease, atrial fibrillation and ischemic stroke were classified as yes or no and defined as 1 or 0, respectively. Similar to the results above, Table 2 showed that there were significant associations between older age (p = 0.001), being male (p = 0.003), hypertension (p = 0.039), ischemic stroke (p = 0.004) and MCA stenosis. However, there was no association between HCY levels and MCA stenosis (p = 0.447).
3.3 | Differences in the indicated factors between the no MCA stenosis group and MCA stenosis group after age and sex matching

Given the influence of age and sex on MCA stenosis and other factors, the two groups were matched for age and sex. As shown in Table 3, the uric acid level in the MCA stenosis group was higher than that in the no MCA stenosis group (p = 0.004) in males. Similar to the results above, there was still no significant difference in HCY levels between the two groups in males (p = 0.540) and females (p = 0.061). For other factors, there was no significant difference between the two groups.

3.4 | Association between MCA stenosis and the indicated factors after age and sex matching

After the groups were matched for age and sex (Table 4), bivariate logistic regression analysis revealed that uric acid (p = 0.003) and ischemic stroke (p = 0.008) were associated with MCA stenosis in males and ischemic stroke (p = 0.035) was associated with MCA stenosis in females. However, there was still no association between HCY levels and MCA stenosis in males (p = 0.709) and females (p = 0.098). For other factors, there was no significant association with MCA stenosis.

4 | DISCUSSION

In this cross-sectional study, we found that there was no significant difference in HCY levels between the no MCA stenosis group and MCA stenosis group before and after age and sex matching. After adjusting for other factors, no association between serum HCY levels and MCA stenosis was found. Meanwhile, we also found that ischemic stroke was more prevalent in individuals with MCA stenosis and that uric acid was higher in males with MCA stenosis. After adjusting for other factors, they were all significantly associated with MCA stenosis.

Elevated serum HCY level is considered to be a risk factor for atherosclerotic diseases, such as ischemic stroke and coronary heart disease (Han et al., 2015; Li et al., 2016; Wang et al., 2006). Lowering HCY with B vitamins and folic acid was considered a promising strategy to prevent cardiovascular and cerebrovascular diseases events in patients. However, several clinical trials have revealed that supplements combining B vitamins and folic acid did not have beneficial effects on the incidence of vascular events (Armitage et al., 2010; Bazzano, Reynolds, Holder, & He, 2006; Bonaa et al., 2006; Ebbing et al., 2008; Lonn et al., 2006; Toole et al., 2004). Therefore, the use of B vitamins and folic acid as secondary prevention in patients with vascular diseases was not supported. However, in the primary prevention clinical trials, folic acid supplementation significantly reduced the risk of first stroke (Huo et al., 2015; Qin et al., 2016).

Why is lowering HCY useful in primary prevention and useless in secondary prevention? Our study may provide an explanation: HCY is not associated with MCA stenosis, which is a common and typical example of cerebral artery stenosis. In secondary prevention, the proportion of patients with cerebral artery stenosis is higher than that in primary prevention. Because reduction in HCY cannot
reverse cerebral artery stenosis to reduce the incidence of first or recurrent stroke, lowering HCY is often useless in secondary prevention and occasionally useless in primary prevention. Researchers believe that initiation of atherosclerosis requires a high HCY concentration, while in the period from atherosclerosis (without stenosis) to stenosis the HCY concentration may be constant. Lowering HCY before initiation of atherosclerosis may have beneficial effects on the prevention of vascular events. In other word, lowering HCY needs to be as early as possible.

There are some differences between our results and those of another study. In the previous study, the author found that hyperhomocysteinemia might be a risk factor for MCA stenosis in asymptomatic residents (Huang et al., 2007). One reason for the differences is the composition of subjects. In the previous study, asymptomatic residents may have a low percentage of atherosclerosis without stenosis, whereas in our study the subjects may have a high percentage of atherosclerosis without stenosis.

Consistent with previous studies, we also found that uric acid was higher in subjects with MCA stenosis. Kumral, Karaman, Orman, & Kabaroglu (2014) demonstrated that higher uric acid level is strongly associated with carotid artery disease. In the article published by Ahn et al., (2018) the authors reported that higher serum uric acid level was associated with an increased risk of intracranial arterial stenosis among middle-aged females but not males. In our study, the uric acid level in females with MCA stenosis was higher than that in those without MCA stenosis, but no significant difference was observed. Age of subjects, position of arterial stenosis and sample size may be responsible for the differences.

There are several limitations in the study. As this is a cross-sectional study, there may be bias in the sample choice. We chose patients in the Neurology Department instead of asymptomatic residents for subjects. We believe that when comparing the differences in HCY levels between MCA stenosis or no stenosis, symptomatic patients may be more appropriate than asymptomatic residents. Moreover, the sample size, especially that of patients with MCA stenosis in the

### TABLE 2 Bivariate logistic regression analysis on MCA stenosis for indicated variables at baseline

| Variable                  | Walds | OR   | 95% CI        | p Value |
|---------------------------|-------|------|---------------|---------|
| Age                       | 11.023| 1.045| 1.018–1.073   | 0.001   |
| Males                     | 8.763 | 0.390| 0.209–0.727   | 0.003   |
| Smoking                   | 0.044 | 0.914| 0.396–2.113   | 0.834   |
| Hypertension              | 4.249 | 1.763| 1.028–3.023   | 0.039   |
| Diabetes mellitus         | 0.178 | 0.847| 0.392–1.832   | 0.673   |
| History of CHD            | 0.484 | 1.222| 0.695–2.147   | 0.487   |
| Atrial fibrillation       | 0.066 | 0.863| 0.281–2.656   | 0.798   |
| History of ischemic stroke| 8.269 | 2.130| 1.272–3.656   | 0.004   |
| HbA1c                     | 0.278 | 1.078| 0.815–1.427   | 0.598   |
| Fasting blood glucose     | 0.001 | 1.002| 0.862–1.165   | 0.976   |
| Uric acid                 | 0.254 | 1.001| 0.997–1.004   | 0.614   |
| TC                        | 0.030 | 0.936| 0.442–1.984   | 0.863   |
| TG                        | 0.286 | 0.592| 0.611–1.325   | 0.592   |
| LDL-C                     | 0.017 | 1.070| 0.390–2.934   | 0.895   |
| Homocysteine              | 0.578 | 1.012| 0.981–1.044   | 0.447   |

Note. Abbreviations: CHD, coronary heart disease; LDL-C, low-density lipoprotein cholesterol; MCA, middle cerebral artery; TC, total cholesterol; TG, triglyceride.

### TABLE 3 Characteristics of patients after age and sex matched

| Variable                  | MCA stenosis group | No MCA stenosis group |
|---------------------------|--------------------|-----------------------|
| Age, year (mean ± SD)     | 75.69 ± 7.12/70.10 ± 9.65 | 72.91 ± 7.52/67.21 ± 9.3 |
| Smoking, N (%)            | 10 (29)            | 38 (37)               |
| Hypertension, N (%)       | 22 (63)/42 (72)    | 48 (47)/68 (54)       |
| Diabetes mellitus, N (%)  | 6 (17)/19 (33)     | 27 (26)/25 (20)       |
| History of CHD, N (%)     | 15 (43)/20 (34)    | 30 (29)/31 (25)       |
| Atrial fibrillation, N (%)| 3 (9)/3 (5)        | 8 (8)/4 (3)           |
| History of ischemic stroke| 20 (57)/28 (48)   | 31 (30)/35 (28)       |
| HbA1c                     | 6.40 ± 1.09/6.68 ± 1.33 | 6.54 ± 1.38/6.37 ± 1.51 |
| Fasting blood glucose     | 5.66 ± 1.09/5.56 ± 2.82 | 6.12 ± 2.03/6.11 ± 2.38 |
| Uric acid                 | 337.83 ± 79.46/273.53 ± 77.19 | 295.26 ± 72.84/280.63 ± 72.10 |
| TC                        | 4.25 ± 0.87/4.75 ± 1.28 | 4.18 ± 1.00/4.98 ± 1.04 |
| TG                        | 1.32 ± 0.52/1.63 ± 1.23 | 1.32 ± 0.80/1.75 ± 1.04 |
| LDL-C                     | 2.21 ± 0.60/2.40 ± 0.89 | 2.15 ± 0.68/2.50 ± 0.78 |
| Homocysteine              | 19.11 ± 8.92/14.91 ± 6.12 | 17.89 ± 10.50/13.11 ± 5.98 |

Note. Abbreviations: CHD, coronary heart disease; LDL-C, low-density lipoprotein cholesterol; MCA, middle cerebral artery; TC, total cholesterol; TG, triglyceride.
study, was small. Future studies including large samples are warranted. Finally, only a Chinese Han population was studied in this report, so the conclusion needs to be verified in other ethnic populations.

In conclusion, this study indicates a lack of association between serum HCY level and MCA stenosis, which may partially explain the negative results of secondary prevention clinical trials focused on lowering serum HCY level with B vitamins and folic acid supplementation to prevent vascular outcomes. Future studies on HCY reduction should focus on primary prevention of ischemic stroke.

ACKNOWLEDGMENTS

We thank all subjects for their participation in the study. We are also grateful to the nurses in the Neurology Department and the technicians in Luoyang Central Hospital Affiliated to Zhengzhou University for their contribution to the study.

CONFLICTS OF INTEREST

None declared.

DATA AVAILABILITY

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Haitao Zhou https://orcid.org/0000-0002-0521-6551

TABLE 4  Bivariate logistic regression analysis on MCA stenosis for indicated variables after age and sex matched

|          | Males | | | | | Females | | | | | |
|----------|-------|---|---|---|---|---|---|---|---|---|---|---|
|          | Walds | OR | 95% CI | p    | Walds | OR | 95% CI | p    |
| Age      | 1.414 | 1.042 | 0.974–1.115 | 0.234 | 0.582 | 1.015 | 0.976–1.056 | 0.445 |
| Smoking  | 0.023 | 0.919 | 0.313–2.700 | 0.878 | / | / | / | / |
| Hypertension | 1.605 | 1.818 | 0.721–4.586 | 0.205 | 4.246 | 2.250 | 1.040–4.865 | 0.039 |
| Diabetes mellitus | 0.298 | 0.679 | 0.169–2.730 | 0.585 | 0.648 | 1.523 | 0.547–4.238 | 0.421 |
| History of CHD | 1.309 | 1.717 | 0.680–4.334 | 0.253 | 0.015 | 1.051 | 0.480–2.298 | 0.902 |
| Atrial fibrillation | 0.814 | 0.456 | 0.083–2.514 | 0.367 | 0.068 | 1.256 | 0.227–6.947 | 0.794 |
| History of ischemic stroke | 7.066 | 3.471 | 1.387–8.689 | 0.008 | 4.445 | 2.173 | 1.056–4.470 | 0.035 |
| HbA1c | 0.778 | 1.251 | 0.761–2.056 | 0.378 | 0.000 | 0.998 | 0.692–1.440 | 0.991 |
| Fasting blood glucose | 0.813 | 0.843 | 0.582–1.221 | 0.367 | 0.001 | 1.003 | 0.840–1.198 | 0.974 |
| Uric acid | 8.612 | 1.010 | 1.003–1.017 | 0.003 | 3.017 | 0.995 | 0.990–1.001 | 0.082 |
| TC | 0.263 | 0.655 | 0.130–3.305 | 0.608 | 0.064 | 0.886 | 0.345–2.272 | 0.801 |
| TG | 0.040 | 1.084 | 0.492–2.387 | 0.842 | 0.257 | 0.879 | 0.533–1.449 | 0.612 |
| LDL–C | 0.393 | 2.062 | 0.215–19.823 | 0.531 | 0.016 | 1.083 | 0.310–3.788 | 0.901 |
| Homocysteine | 0.139 | 0.991 | 0.944–1.040 | 0.709 | 2.736 | 1.048 | 0.991–1.108 | 0.098 |

Note. Abbreviations: CHD, coronary heart disease; LDL–C, low-density lipoprotein cholesterol; MCA, middle cerebral artery; TC, total cholesterol; TG, triglyceride.

REFERENCES

Ahn, J. K., Hwang, J., Hwang, J. H., Yoon, W. T., Chung, P. W., & Ryu, S. (2018). The association between serum uric acid and asymptomatic intracranial arterial stenosis in middle-aged Koreans. Nutrition, Metabolism and Cardiovascular Diseases, 28, 14–22. https://doi.org/10.1016/j.numecd.2017.10.019
Armitage, J. M., Bowman, L., Clarke, R. J., Wallendszus, K., Bulbulia, R., Rahimi, K., ... Collins, R. (2010). Effects of homocysteine-lowering with folic acid plus vitamin b12 vs placebo on mortality and major morbidity in myocardial infarction survivors: A randomized trial. JAMA, 303, 2486–2494. https://doi.org/10.1001/jama.2010.840
Bazzano, L. A., Reynolds, K., Holder, K. N., & He, J. (2006). Effect of folic acid supplementation on risk of cardiovascular diseases: A meta-analysis of randomized controlled trials. JAMA, 296, 2720–2726. https://doi.org/10.1001/jama.296.22.2720
Bonaa, K. H., Njolstad, I., Ueland, P. M., Schirmer, H., Tverdal, A., Steigen, T., ... Rasmussen, K. (2006). Homocysteine lowering and cardiovascular events after acute myocardial infarction. New England Journal of Medicine, 354, 1578–1588. https://doi.org/10.1056/nejmoa055227
Chen, H., Li, Z., Hong, H., Xing, S., Liu, G., Zhang, A., ... Zeng, J. (2015). Relationship between visible branch arteries distal to the stenosis on magnetic resonance angiography and stroke recurrence in patients with severe middle cerebral artery trunk stenosis: A one-year follow up study. BMC Neurology, 15, 167–175. https://doi.org/10.1186/s12883-015-0423-0
Clarke, R., Daly, L., Robinson, K., Naughten, E., Cahalane, S., Fowler, B., ... Graham, I. (1991). Hyperhomocysteinemia: An independent risk factor for vascular disease. New England Journal of Medicine, 324, 1149–1155. https://doi.org/10.1056/nejm199104253241701
Dennis, V. W., Nurko, S., & Robinson, K. (1997). Hyperhomocysteinemia: Detection, risk assessment, and treatment. Current Opinion in Nephrology and Hypertension, 6, 483–488. https://doi.org/10.1097/0001552-199709000-00013
Dikmen, M., Ozbabalik, D., Gunes, H. V., Degirmenci, I., Bal, C., Ozdemir, G., & Basaran, A. (2006). Acute stroke in relation to
homocysteine and methylenetetrahydrofolate reductase gene polymorphisms. Acta Neurologica Scandinavica, 113, 307–314. https://doi.org/10.1111/j.1600-0404.2005.00556.x

Ebbing, M., Bleie, O., Ueland, P. M., Nordrehaug, J. E., Nilsen, D. W., Vollset, S. E., ... Nygård, O. (2008). Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: A randomized controlled trial. JAMA, 303, 795–804. https://doi.org/10.1001/jama.303.7.795

Han, L., Wu, Q., Wang, C., Hao, Y., Zhao, J., Zhang, L., ... Duan, S. (2015). Homocysteine, ischemic stroke, and coronary heart disease in hypertensive patients: A population-based, prospective cohort study. Stroke, 46, 1777–1786. https://doi.org/10.1161/strokeaha.115.009111

Huang, H. W., Guo, M. H., Lin, R. J., Chen, Y., Luo, Q., Zhang, Y., & Wong, K. S. (2007). Hyperhomocysteinemia is a risk factor of middle cerebral artery stenosis. Journal of Neurology, 254, 364–367. https://doi.org/10.1007/s00415-006-0377-7

Huo, Y., Li, J., Qin, X., Huang, Y., Wang, X., Gottesman, R. F., ... Hou, F. F. (2015). Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: The CSPPT randomized clinical trial. JAMA, 313, 1325–1335. https://doi.org/10.1001/jama.2015.2274

Jeng, J. S., Hsieh, F. I., Yeh, H. L., Chen, W. H., Chiu, H. C., Tang, S. C., ... Taiwan Stroke Registry Investigators (2017). Impact of MCA stenosis on the early outcome in acute ischemic stroke patients. PLoS One, 12, e0175434. https://doi.org/10.1371/journal.pone.0175434

Kumral, E., Karaman, B., Orman, M., & Kabaroglu, C. (2014). Association of uric acid and carotid artery disease in patients with ischemic stroke. Acta Neurologica Scandinavica, 130, 11–17. https://doi.org/10.1111/ane.12208

Kwon, H. M., Lee, Y. S., Bae, H. J., & Kang, D. W. (2014). Homocysteine as a predictor of early neurological deterioration in acute ischemic stroke. Stroke, 45, 871–873. https://doi.org/10.1161/strokeaha.113.004099

Li, Y., Huang, T., Zheng, Y., Muka, T., Trupp, J., & Hu, F. B. (2016). Folic acid supplementation and the risk of cardiovascular diseases: A meta-analysis of randomized controlled trials. Journal of the American Heart Association, 5, e003768. https://doi.org/10.1161/jaha.116.003768

Lonn, E., Yusuf, S., Arnold, M. J., Sheridan, P., Pogue, J., Micks, M., & McQueen, M. J. (2006). Homocysteine lowering with folic acid and B vitamins in vascular disease. New England Journal of Medicine, 354, 1567–1577. https://doi.org/10.1056/nejmoa060900

McCully, K. S. (1969). Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. American Journal of Pathology, 58, 111–128.

Qin, X., Li, J., Spence, J. D., Zhang, Y., Li, Y., Wang, X., ... Huo, Y. (2016). Folic acid therapy reduces the first stroke risk associated with hypercholesterolemia among hypertensive patients. Stroke, 47, 2805–2812. https://doi.org/10.1161/STROKEAHA.116.014578

Toole, J. F., Malinow, M. R., Chambless, L. E., Spence, J. D., Pettigrew, L. C., Howard, V. J., ... Stamper, M. (2004). Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The vitamin intervention for stroke prevention (visp) randomized controlled trial. JAMA, 291, 565–575.

Wald, D. S., Law, M., & Morris, J. K. (2002). Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. BMJ, 325, 1202–1208. https://doi.org/10.1136/bmj.325.7374.1202

Wang, H., Fan, D., Zhang, H., Fu, Y. U., Zhang, J., & Shen, Y. (2004). Serum level of homocysteine is correlated to carotid artery atherosclerosis in Chinese with ischemic stroke. Neurological Research, 26, 25–30. https://doi.org/10.1179/016164104691834

Yokote, H., Shiraishi, A., Shintani, S., & Shiigai, T. (2007). Acute multiple brain infarction in large-artery atherosclerosis is associated with hyperhomocyst(e)inemia. Acta Neurologica Scandinavica, 116, 243–247. https://doi.org/10.1111/j.1600-0404.2007.00873.x

Zhang, D., Xie, X., Chen, Y., Hammock, B. D., Kong, W., & Zhu, Y. I. (2012). Homocysteine upregulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Circulation Research, 110, 808–817. https://doi.org/10.1161/circresaha.111.259325

How to cite this article: Zhou H, Huang C, Liu R, Liu C, Ma C, Ren X. Lack of association between serum homocysteine level and middle cerebral artery stenosis. Brain Behav. 2019;9:e01297. https://doi.org/10.1002/brb3.1297